Abstract
Denosumab inhibits the formation, function, and survival of osteoclasts by blocking the interaction of receptor activator of nuclear factor-kappaB (RANK) ligand with its osteoclastic receptor RANK. Treatment with denosumab results in a significant risk reduction of vertebral, hip, and nonvertebral fractures in women with postmenopausal osteoporosis.
Treatment is not associated with important side effects.